Skip to main content

Table 4 Details of included observational studies*

From: Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

Reference

Jacobs 2009

Akagi 2008

Channick 2006

Hoeper 2003

Mathai 2007

Hoeper 2004

Baseline therapy

ERA + PDE5i

Pr

ERA

Pr

ERA

None

Add-on therapy

Pr

ERA

Pr

ERA

PDE5i

ERA

Prostacyclin analogue

intravenous epoprostenol and subcutaneous treprostinil

intravenous epoprostenol

inhaled treprostinil

oral beraprost and inhaled iloprost

NA

NA

Treatment dose

10-20 ng/kg/min subcutaneous treprostinil, 38.4 end of observation. 6-8 ng/kg/min intravenous epoprostenol, 16.2 end of observation

62.5 mg bosentan twice daily

6 on 30 mcg inhaled treprostinil 4 daily 6 on 45 mug 4 daily.

62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks.

20 mg sildenafil (up to 100 mg included) once daily

62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks.

Patients at end of study

10

7

11

20

25

9

Duration

16 weeks

1 year

12 weeks

6 months

12 weeks

3 months

Change 6MWD

41 (38)

3 (23)

67 (45)

58 (9.6)

20 (28)

57 (35)

Baseline 6MWD

387 (30)

392 (16)

339 (26)

346 (23.7)

265 (19)

346

Age

37

32

51.2

46

56.2

39

Sex (% male)

0.19

0.13

0.09

0.30

0.04

0.22

STATUS

3

2

3

3.2

3.1

3.1

PVR

957.8¶

776

744

1147

928

1549

  1. *ERA are endothelin receptor antagonists, PDE5i are phosphodiesterase 5 inhibitors, Pr are prostacyclin analogues. iv ep is intravenous epoprostenol, inh ilp is inhaled iloprost, sc trep is subcutaneous treprostinil.
  2. ¶Imputed from linear model for PVR based on Age, right arterial pressure, MPAP and cardiac output.